Drug Trial Radar · NCT02586805
Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
Last checked: Nov 20, 2026Latest source record: Jun 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
125
Actual
Start
Mar 3, 2016
Primary completion
Apr 13, 2017
Study completion Apr 13, 2017
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Dyax Corp.
- First posted
- Oct 26, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.
Conditions
- Hereditary Angioedema (HAE)
Interventions
DX-2930 - 300mg/2wkDrug
300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
DX-2930 - 300mg/4wkDrug
300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
DX-2930 - 150mg/4wkDrug
150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
PlaceboDrug
Placebo administered every 2 weeks by subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Investigator Confirmed Hereditary Angioedema (HAE) Attacks During Treatment PeriodTime frame: From Day 0 to Day 182
Locations
41 sites in 7 countries. Site status is shown where the registry gives one.
Clinical Research Center of Alabama, LLC
Birmingham, Alabama
Medical Research of Arizona
Scottsdale, Arizona
UC San Diego School of Medicine
San Diego, California
AIRE Medical of Los Angeles
Santa Monica, California
Allergy & Asthma Clinical Research
Walnut Creek, California
IMMUNOe International Health & Research Centers
Centennial, Colorado
Asthma and Allergy Associates, P.C.
Colorado Springs, Colorado
University of South Florida
Tampa, Florida
University of Kansas Medical Center
Kansas City, Kansas
Institute of Asthma & Allergy, P.C.
Chevy Chase, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan Hospital and Health System
Ann Arbor, Michigan
Midwest Immunology Clinic
Plymouth, Minnesota
Washington University School of Medicine
St Louis, Missouri
Hudson-Essex Allergy, LLC
Belleville, New Jersey
Atlantic Research Center, LLC
Ocean City, New Jersey
Winthrop University Hospital
Mineola, New York
The Mount Sinai Medical Center
New York, New York
American Health Research
Charlotte, North Carolina
Duke Asthma, Allergy and Airway Center
Durham, North Carolina
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio
Optimed Research, LTD
Columbus, Ohio
Toledo Institute of Clinical Research
Toledo, Ohio
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania
Austin Regional Clinic
Austin, Texas
AARA Research Center
Dallas, Texas
Intermountain Clinical Research
Draper, Utah
Allergy Associates of Utah
Murray, Utah
Virginia Commonwealth University
Richmond, Virginia
Marycliff Allergy Specialists
Spokane, Washington
Children's Hospital of Wisconsin
Milwaukee, Wisconsin
Ottawa Allergy Research Corporation
Ottawa, Ontario, Canada
Gordon Sussman Clinical Research Inc.
Toronto, Ontario, Canada
Clinique Specialisee en Allergie de la Capitale
Québec, Quebec, Canada
Charité - University of Berlin
Berlin, Germany
Hautklinik und Poliklinik der Universitätsmedizin
Mainz, Germany
HZRM Hamophilie-Zentrum Rhein Main
Mörfelden-Walldorf, Germany
Hospital L. Sacco, Milan University
Milan, Italy
Triumpharma
Amman, Jordan
Sociedad Alergologica
San Juan, PR, Puerto Rico
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.